These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
149 related items for PubMed ID: 6433471
1. Production of antihemophilic factor in France. Allain JP. Scand J Haematol Suppl; 1984; 40():499-503. PubMed ID: 6433471 [No Abstract] [Full Text] [Related]
2. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography. Sultan Y, Boyeldieu D, Stieltjes N. Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717 [Abstract] [Full Text] [Related]
3. The use of facoor VIII and factor IX concentrates during surgery. George JN, Breckenridge RT. JAMA; 1970 Nov 30; 214(9):1673-6. PubMed ID: 5536529 [No Abstract] [Full Text] [Related]
4. The management of hemophilia patients with inhibitors. Nilsson IM. Transfus Med Rev; 1992 Oct 30; 6(4):285-93. PubMed ID: 1421831 [No Abstract] [Full Text] [Related]
5. Prophylaxis in children with hemophilia: is it the optimal treatment? Lusher JM. Thromb Haemost; 1997 Jul 30; 78(1):726-9. PubMed ID: 9198246 [No Abstract] [Full Text] [Related]
10. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Hedner U. Thromb Haemost; 1999 Aug 30; 82(2):531-9. PubMed ID: 10605747 [No Abstract] [Full Text] [Related]
11. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network. Berntorp E, Shapiro AD, Waters J, Astermark J. Haemophilia; 2014 Sep 30; 20(5):e362-4. PubMed ID: 25156443 [No Abstract] [Full Text] [Related]
12. [Principles of modern therapy for hemophilia A and B in childhood]. Ströder J, Ambs E. Dtsch Med Wochenschr; 1968 Mar 22; 93(12):539-41. PubMed ID: 5639667 [No Abstract] [Full Text] [Related]
13. Prophylaxis in children with haemophilia - the Polish experience. Klukowska A, Urasinski T, Janik-Moszant A, Bobrowska H, Balwierz W, Woznica-Karczmarz I, Dobaczewski G, Wlazlowski M, Koltan A, Badowska W, Dakowicz L, Karolczyk G, Kostrzewska M, Korczowski B, Wasinski D, Pietrys D, Laguna P, Wysocka M. Haemophilia; 2014 Jan 22; 20(1):e108-10. PubMed ID: 24251651 [No Abstract] [Full Text] [Related]
14. Switching haemophilia products and inhibitor risk: a United States' perspective. Nance D, Rodgers GM. Eur J Haematol; 2015 Apr 22; 94(4):283. PubMed ID: 25800968 [No Abstract] [Full Text] [Related]
17. Therapeutic properties and safety of recombinant factor VIII and factor IX. Zdziarska J, Chojnowski K, Klukowska A, Łetowska M, Mital A, Podolak-Dawidziak M, Windyga J, Zawilska K, Working Group on Hemostasis of the Polish Society of Hematologists and Transfusiologists. Pol Arch Med Wewn; 2009 Jun 22; 119(6):403-9. PubMed ID: 19694223 [Abstract] [Full Text] [Related]
20. [Blood derivatives in the treatment of hemophilia in Spain. Present and future needs]. Medarde A, Ayesa C, Alfonso L, Muñóz A. Sangre (Barc); 1979 Jun 22; 24(5-C):942-6. PubMed ID: 121170 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]